Inactive Instrument

AMAG Pharmaceuticals, Inc.

AMAG

US00163U1060

AMAG Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2020; Announces Impairment of Assets for the Fourth Quarter of 2019

March 04, 2020 at 05:30 pm IST

AMAG Pharmaceuticals, Inc. reaffirmed earnings guidance for the year 2020. For the year, the company expects total revenue in the range of $230-280 million and operating income in the range of $2-$32 million.

The company announced impairment of assets of $155.0 million for the fourth quarter of 2019.

Latest news about AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. Files Submission in Response to the Food and Drug Administration’s Notice of Opportunity for A Hearing and Proposal to Withdraw Approval of Makena® (Hydroxyprogesterone Caproate Injection)	14/20/14	CI
AMAG Pharmaceuticals, Inc. Announces Management Changes	17/20/17	CI
AMAG Pharmaceuticals, Inc. Appoints Michael Porter as Chief Executive Officer	17/20/17	CI
AMAG Pharmaceuticals, Inc. Appoints Ozgur Kilic as Chief Financial Officer	17/20/17	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 1000	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P Composite 1500	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P Global BMI Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 600 Health Care	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 600	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P TMI Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2000 Value Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Value Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell Small Cap Completeness Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000 Value Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2000 Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000 Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell Small Cap Comp Value Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2000 Value-Dynamic Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Value-Dynamic Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Dynamic Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000E Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000E Value Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell Microcap Index	13/20/13	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell Microcap Value Index	13/20/13	CI

Chart AMAG Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals